A detailed history of State Street Corp transactions in Vor Biopharma Inc. stock. As of the latest transaction made, State Street Corp holds 115,934 shares of VOR stock, worth $100,862. This represents 0.0% of its overall portfolio holdings.

Number of Shares
115,934
Previous 115,934 -0.0%
Holding current value
$100,862
Previous $115,000 29.57%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$1.0 - $2.2 $541,773 - $1.19 Million
-541,773 Reduced 82.37%
115,934 $115,000
Q1 2024

May 15, 2024

BUY
$1.8 - $2.85 $89,460 - $141,645
49,700 Added 8.17%
657,707 $1.56 Million
Q4 2023

Feb 14, 2024

BUY
$1.66 - $2.63 $3,486 - $5,523
2,100 Added 0.35%
608,007 $1.37 Million
Q3 2023

Nov 14, 2023

SELL
$2.1 - $3.35 $49,095 - $78,319
-23,379 Reduced 3.72%
605,907 $1.28 Million
Q2 2023

Aug 14, 2023

BUY
$3.09 - $5.33 $1.79 Million - $3.08 Million
578,173 Added 1131.17%
629,286 $1.94 Million
Q1 2023

May 15, 2023

BUY
$4.68 - $6.96 $5,616 - $8,352
1,200 Added 2.4%
51,113 $274,000
Q4 2022

Feb 14, 2023

BUY
$3.77 - $7.43 $32,799 - $64,641
8,700 Added 21.11%
49,913 $331,000
Q2 2022

Aug 15, 2022

SELL
$3.89 - $6.44 $940,847 - $1.56 Million
-241,863 Reduced 85.44%
41,213 $205,000
Q1 2022

May 16, 2022

BUY
$6.04 - $12.23 $108,061 - $218,806
17,891 Added 6.75%
283,076 $1.71 Million
Q4 2021

Feb 14, 2022

BUY
$11.32 - $18.02 $328,981 - $523,697
29,062 Added 12.31%
265,185 $3.08 Million
Q3 2021

Nov 15, 2021

BUY
$12.24 - $20.38 $420,076 - $699,441
34,320 Added 17.01%
236,123 $3.7 Million
Q2 2021

Aug 16, 2021

BUY
$18.65 - $38.78 $601,872 - $1.25 Million
32,272 Added 19.04%
201,803 $3.76 Million
Q1 2021

May 17, 2021

BUY
$30.96 - $54.08 $5.25 Million - $9.17 Million
169,531 New
169,531 $7.31 Million

Others Institutions Holding VOR

About Vor Biopharma Inc.


  • Ticker VOR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,056,300
  • Market Cap $33.1M
  • Description
  • Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AM...
More about VOR
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.